Nextmune concentrate and solvent for suspension for

Authorised

 Infectious bursal disease virus, strain Winterfield 2512 (intermediate plus), Live

Product identification

injection for chickens

Medicine name:

Nextmune concentrate and solvent for suspension for injection for chickens Nextmune koncentrāts un šķīdinātājs suspensijas injekcijām pagatavošanai vistām

Active substance:

Infectious bursal disease virus, strain Winterfield 2512 (intermediate plus), Live

Target species:

Chicken (broiler)

Chicken (embryonated eggs)

Route of administration:

Subcutaneous use

In ovo

Product details

Active substance and strength:

Infectious bursal disease virus, strain Winterfield 2512 (intermediate plus), Live 2.70 log 10 50% embryo infective dose / 1.00 Dose

Pharmaceutical form:

Concentrate and solvent for suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

•

Chicken (broiler)

- Meat and offal. 0 day

In ovo:

•

Chicken (embryonated eggs)

- Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AD09

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Latvia

Package description:

bag containing 1600 ml of solvent

bag containing 1200 ml of solvent

bag containing 800 ml of solvent

bag containing 400 ml of solvent

One ampoule of 5 ml containing 8000 doses

One ampoule of 5 ml containing 4000 doses

One ampoule of 5 ml containing 2000 doses

One ampoule of 2 ml containing 4000 doses

One ampoule of 2 ml containing 2000 doses

bag containing 1000 ml of solvent

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Ceva-Phylaxia Zrt.

Marketing authorisation date:

21/09/2020

Manufacturing sites for batch release:

Ceva-Phylaxia Zrt.

Responsible authority:

Food And Veterinary Service

Authorisation number:

V/DCP/20/0046

Date of authorisation status change:

21/09/2020

Reference member state:

Spain

Procedure number:

ES/V/0337/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia France Germany Greece Hungary Ireland Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia United Kingdom (Northern Ireland) To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents
Summary of Product Characteristics
Labelling
Combined File of all Documents
This document does not exist in this language (English). You can find it in another language below.

Source URL: https://medicines.health.europa.eu/veterinary/600000017497